SCHEMBL2404080

SCHEMBL2404080

COC(C)/C=C(\C#N)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC16A3 O15427 3/20 0.38
SLC16A1 P53985 3/20 0.38
CISD1 Q9NZ45 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
GPR35 Q9HC97 1/20 0.38
EGFR P00533 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231637 1.00 KDM4E (0.39) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL20395654 0.87 SLC16A3 (0.33) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL21248116 0.87 KDM4E (0.36) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL1275703 0.82 KDM4E (0.37) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL28712283 0.79 KDM4E (0.35) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL450204 0.79 CYP2C9 (0.38) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL15441 0.79 KDM4E (0.42) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL22246044 0.79 KDM4E (0.42) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL15440 0.79 KDM4E (0.42) KDM4ELMNAPKMKMT2ASLC16A3
SCHEMBL11051248 0.77 KDM4E (0.41) KDM4ELMNAPKMKMT2ASLC16A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897978-B2 Hybrid light-curing composition DYMAX CORPORATION (US) 2024-02-13 US claimed
US-20210301045-A1 HYBRID LIGHT-CURING COMPOSITION DYMAX CORPORATION 2021-09-30 US claimed
US-9550883-B2 Cyanoacrylate compositions Henkel IP & Holding GmbH (DE) 2017-01-24 US claimed
US-20140326407-A1 CYANOACRYLATE COMPOSITIONS Henkel US IP LLC (US) 2014-11-06 US claimed
EP-0963420-B1 RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS HENKEL LOCTITE CORP (US) 2007-04-25 EP claimed
US-7064155-B2 Luminescing and/or fluorescing radiation-curable, cyanoacrylate-containing compositions HENKEL CORPORATION (US) 2006-06-20 US claimed
US-6906112-B1 Radiation-curable, cyanoacrylate-containing compositions HENKEL CORPORATION (US) 2005-06-14 US claimed
US-6867241-B2 Radiation-curable, cyanoacrylate-containing compositions HENKEL CORPORATION (US) 2005-03-15 US claimed
US-6726795-B1 COMPOSITION COMPRISING 2-CYANOACRYLATE MONOMER, METALLOCENE, PHOTOINITIATOR, SULFUR-CONTAINING COMPOUND, AND POLYMETHYL METHACRYLATE Henkel IP & Holding GmbH (DE) 2004-04-27 US claimed
US-20040034116-A1 Luminescing and/or fluorescing radiation-curable, cyanoacrylate-containing compositions HENKEL LOCTITE CORPORATION 2004-02-19 US claimed
US-20030162857-A1 Radiation-curable, cyanoacrylate-containing compositions LOCTITE CORPORATION 2003-08-28 US claimed
WO-2003065841-A1 LUMINESCING AND/OR FLUORESCING RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS HENKEL CORPORATION (US) 2003-08-14 WO claimed
WO-2003064483-A1 RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS HENKEL CORPORATION (US) 2003-08-07 WO claimed
EP-0963420-A4 RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS LOCTITE CORP (US) 2003-01-15 EP claimed
US-6433036-B1 METALLOCENE AND PHOTOINITIATOR; EXPOSURE TO ELECTROMAGNETIC RADIATION LOCTITE CORPORATION 2002-08-13 US claimed
EP-0963420-A1 RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS LOCTITE CORPORATION (US) 1999-12-15 EP claimed
WO-1998038260-A9 RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS 1999-02-11 WO claimed
WO-1998038260-A1 RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS LOCTITE CORPORATION (US) 1998-09-03 WO claimed
EP-4331796-A1 ACTINIC RADIATION CURABLE CYANOACRYLATE COMPOSITIONS FOR CERAMICS AND INVESTMENT CASTING ARKEMA FRANCE (FR) 2024-03-06 EP disclosed
WO-1998038260-A1 RADIATION-CURABLE, CYANOACRYLATE-CONTAINING COMPOSITIONS LOCTITE CORPORATION (US) 1998-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210301045-A1 HYBRID LIGHT-CURING COMPOSITION MUS81, MAT2B, MAT1A KDM4E 1835/4885LMNA 1479/4885PKM 3482/4885
US-11897978-B2 Hybrid light-curing composition MUS81, MAT2B, MAT1A KDM4E 1835/4885LMNA 1479/4885PKM 3482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.